KRAS and non-small cell lung carcinoma: The results indicated that 10 days of treatment with both trametinib and anlotinib prevented nearly all the rebound of ERK phosphorylation and AKT phosphorylation in various KRAS-mutant NSCLC cells (Fig. 2g).